
Aurobindo Pharma Ltd. share price
NSE: AUROPHARMA · Healthcare
₹1,794.00 -1.60%
Closing price data, updated 17 Nov 2026. 52-week range: -3.5% from high, +62.2% above low.
Price₹1,794.00
Market cap₹1,03,223 Cr
P/E25.9
P/B2.62
ROE9.9%
ROCE13.5%
Debt / equity0.21
Dividend yield0.00%
EPS₹69.35
Book value₹684.77
Operating margin15.6%
Dipscan score60 / 100
Share: WhatsAppX / TwitterTelegram
Aurobindo Pharma Ltd. shareholding pattern
As of Sep 2026: Promoters 51.88%, FIIs 17.41%, DIIs 24.42%, Government 0.00%, Public 5.02%, Others 1.27%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 51.88% | 51.88% | 51.82% | 51.82% | 51.82% | 51.82% |
| FIIs | 17.41% | 16.38% | 15.24% | 13.94% | 14.21% | 14.37% |
| DIIs | 24.42% | 25.10% | 25.87% | 27.68% | 27.60% | 26.93% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 5.02% | 5.36% | 5.74% | 5.36% | 5.25% | 5.67% |
| Others | 1.27% | 1.28% | 1.34% | 1.19% | 1.13% | 1.20% |
| No. of Shareholders | 233,737 | 239,073 | 241,298 | 236,859 | 247,662 | 272,208 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -1.60% | -0.33% | +7.88% | +7.85% | +18.74% | +55.35% |
Growth
| Sales growth, 3 years | +10.7% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +22.1% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Weaknesses
- Stock is trading at 2.62 times its book value
- The company has delivered a poor sales growth of 6.32% over past five years.
- Company has a low return on equity of 10.8% over last 3 years.
- Company might be capitalizing the interest cost
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Aurobindo Pharma Ltd.?
Aurobindo Pharma Ltd. (AUROPHARMA) last closed at ₹1,794.00 (-1.60% on the day).
What is the market cap of Aurobindo Pharma Ltd.?
About ₹1,03,223 Cr.
What is the P/E ratio of Aurobindo Pharma Ltd.?
The price-to-earnings ratio is 25.9, and return on equity is 9.9%.
Figures are calculated from company results and exchange prices and are for information only.